AbbVie (ABBV) surges 3.1% to $284.58 on new Skyrizi Phase 3 data

AbbVie climbed steadily through the session, reaching $284.58 by mid-afternoon, a gain that stands out for a company of this size and defensive profile. For a pharmaceutical name of that scale, a single-session move of this magnitude signals that something fundamental has shifted in how investors are valuing the business.

The catalyst landing the day before was new Phase 3 data from the AFFIRM trial examining subcutaneous SKYRIZI in Crohn's disease. Positive Phase 3 readouts in a flagship indication can meaningfully expand a drug's addressable market, and SKYRIZI sits at the center of AbbVie's post-Humira growth story.

Immunology has become the growth engine that investors are actively repricing within AbbVie's portfolio. As Humira faced biosimilar pressure, the company leaned heavily on SKYRIZI and Rinvoq to carry the revenue trajectory forward, and data that reinforces confidence in that strategy tends to move the stock sharply.

The market is treating the AFFIRM data as a meaningful confirmation of the immunology strategy. Investors watching the immunology pipeline will want to follow how the data is received by the medical community and what, if any, regulatory implications follow.